$INTS
Intensity Therapeutics, Inc. Common stock
XNAS•Health Care•Biological Products, (No Diagnostic Substances)
Intensity Therapeutics, Inc. Common stock
XNAS•Health Care•Biological Products, (No Diagnostic Substances)
Why is INTS down today? It is at $2.43 (-0.80%), and our scanner flagged it 4 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment INTS spikes, and full due diligence on INTS — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $INTS 4 times in the last 30 days. Create a free account to track $INTS, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
The market is closed. Here is how INTS traded in the last session, Friday (last price and move above). Our scanner fired 3 unusual-volume and momentum alerts on INTS on Friday, peaking at 11.8x its normal volume.
Likely catalystIntensity Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business UpdateReported New patient enrollment activities resumed in a limited number of U.S. sites in the soft tissue sarcoma Phase 3 INVINCIBLE-3 Study in the third quarter of 2026Reported New patient enrollment and treatment resumed in the presurgical triple negative breast cancer (“TNBC”) Phase 2 INVINCIBLE-4 Study in the third quarter of 2026Reported Cash and cash equivalents of $8.5 million as of September 30, 2026, from an SEC filing. Read it →We could not reach SEC EDGAR, so the dilution check did not run. This is not a clean result - verify on EDGAR before trading.
Sources: float & market cap via Polygon · short interest via FINRA · borrow & shortability via Alpaca · SSR from Reg SHO 201 · filings & dilution via SEC EDGAR · analysts via Nasdaq.
Auto-generated from public data for research and education. Not investment advice.
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Talamo Joseph Officer | Acquired (grant/award) | +1K 0.03% of company | added 95% | 2K | $4K at $3.48 | Jun 30, 26 |
Wesolowski John M Officer | Acquired (grant/award) | +4K 0.1% of company | added 100% | 7K | $13K at $3.48 | Jun 30, 26 |
Bender Lewis H Officer | Acquired (grant/award) | +38K 1.1% of company | added 47% | 119K | $231K at $6.11 | Mar 26, 26 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
The tickers our scanner is lighting up most over the last 48 hours.
Comparable names in biological products, (no diagnostic substances), closest in size first.
The market is closed. Here is how INTS traded in the last session, Friday (last price and move above). Our scanner fired 3 unusual-volume and momentum alerts on INTS on Friday, peaking at 11.8x its normal volume.
INTS last traded at $2.43, down 0.80% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
The INTS Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged INTS 4 times in the last 30 days.
INTS (Intensity Therapeutics, Inc. Common stock) trades on XNAS, with a market cap of about $8M in the Biological Products, (No Diagnostic Substances) sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge INTS for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$INTS discussion
Sign in to ask a question or join the discussion.